智通财经网·2025-05-14 01:41Group 1 - JD Health's stock rose over 6% following the release of its Q1 2025 earnings, reaching HKD 40.3 with a trading volume of HKD 145 million [1] - For Q1 2025, JD Health reported revenue of RMB 16.645 billion, a year-on-year increase of 25.5%, and operating profit of RMB 1.071 billion, up 119.8% year-on-year [1] - The company launched several innovative drugs in Q1 2025, expanding treatment options for patients [1] Group 2 - According to a report by Credit Lyonnais, JD Health's Q1 performance indicators are expected to be robust, with total revenue projected to increase by 15% year-on-year to RMB 15.3 billion [2] - The increase in revenue is attributed to heightened demand for pharmaceuticals due to a flu outbreak since January and improved user traffic from a trade-in promotion on the JD platform [2] - The report anticipates a 20% year-on-year increase in pharmaceutical sales, with health products and medical devices expected to maintain over 10% growth [2]